# US 2016/0354437 A1 · Compositions and methods for modulation of immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354437 A1
- Document ID: US20160354437A1
- Status: Published application
- Kind: A1
- Application number: 15/117,629
- Filed: 2015-02-13
- Published: 2016-12-08
- Earliest claimed: 2014-02-13
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Christian Stehlik
- Web page: https://patentgrep.com/patent/US20160354437A1

## CPC

- A61K 38/1709: {from mammals}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).

## Claims

### Claim 1

A method of treating or preventing a disease or condition associated with inflammation comprising administering a composition that increases the activity of POP1, POP2, and/or POP3.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises a POP1, POP2, and/or POP3 polypeptide, peptide, or peptidomimitic.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polypeptide or peptide comprises 100% sequence identity with all or a portion of POP1, POP2, or POP3.

### Claim 4 (depends on 2)

The method of claim 2, wherein the polypeptide or peptide comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises an agent that enhances the inflammasome inhibitory activity of POP1, POP2, and/or POP3.

### Claim 6 (depends on 5)

The method of claim 5, wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease or condition is an autoimmune disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease or condition is an inflammatory disease.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is co-administered with one or more additional treatments for the disease or condition

### Claim 10

A method of treating or preventing infection comprising administering a composition that inhibits the activity of POP1, POP2, and/or POP3.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody.

### Claim 12

The POP1, POP2, or POP3 protein, polypeptide, or peptide that comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3.

### Claim 13

A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament.

### Claim 13

A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament.

### Claim 14 (depends on 13)

The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13, comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1 or POP3.

### Claim 14 (depends on 13)

The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13, comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3.

### Claim 15 (depends on 13)

The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.

### Claim 15 (depends on 13)

The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.

### Claim 16

A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.

### Claim 16

A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.

### Claim 17

A POP1, POP2, or POP3 inhibitor.